On January 12, 2025, Regulation (EU) 2021/2282 on Health Technology Assessment (HTAR) became applicable for new oncology medicines and Advanced Therapy Medicinal Products (ATMPs), reshaping European market-access dossier localization.

January 12, 2025: Mandatory Joint Clinical Assessments (JCAs) Launch

On January 12, 2025, the European Union's Health Technology Assessment Regulation (Regulation (EU) 2021/2282, HTAR) entered into application for its first wave of innovative therapies: new active substances indicated for the treatment of cancer and all Advanced Therapy Medicinal Products (ATMPs). Under the HTAR framework, EU Member States conduct a single central Joint Clinical Assessment (JCA) running in parallel with the European Medicines Agency's centralized marketing authorization procedure, evaluating relative clinical effectiveness and safety across PICO (Population, Intervention, Comparator, Outcome) scopes.

Bridging EU-Level JCA Dossiers with National Pricing & Reimbursement Submissions

While the central JCA dossier is submitted in English within strict 100-day regulatory timelines, individual EU Member States retain exclusive competence over national value assessments, health-economic modeling, and pricing and reimbursement negotiations (such as AMNOG in Germany, AIFA dossiers in Italy, HAS transparency filings in France, and CIPM in Spain). Market access teams therefore rely on specialized medical and health-economics translators to localize JCA findings, pharmacoeconomic models, and national value dossiers rapidly across Member State languages.

Benötigen Sie zertifizierte mehrsprachige Fachübersetzungen, beglaubigte Urkundenübersetzungen oder ISO-konforme Lokalisierung für Ihre internationalen Projekte? Fordern Sie ein kostenloses maßgeschneidertes Angebot von Alphatrad an und erhalten Sie innerhalb von 24 Stunden einen detaillierten Ablaufplan.